Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Canagliflozin 100 mg; Drug: Placebo/sitagliptin 2x50 mg; Drug: Canagliflozin 300 mg
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010
Conditions: Hyperphosphatemia; End-Stage Renal Disease
Intervention: Drug: ferric citrate
Sponsor: Keryx Biopharmaceuticals
Not yet recruiting - verified February 2010